{"release":"wpf-claim-checks","version":"1.6.0","checkedOn":"2026-11-16","verificationLabel":"AI-assisted source verification","humanReview":"none recorded","claim":{"id":"tirzepatide-semaglutide-same-trial","claimWording":"Tirzepatide and semaglutide have been compared head to head in a randomized trial.","wordingKind":"representative","quoted":null,"title":"Tirzepatide and semaglutide in the same trial","peptides":["tirzepatide","semaglutide"],"aliases":["Mounjaro","Zepbound","Wegovy","Ozempic"],"topics":["interpretation"],"verdict":"supported_within_scope","plainAnswer":"Yes, in SURMOUNT-5, a 72-week open-label trial in adults with obesity: -20.2% with tirzepatide against -13.7% with semaglutide. Other weight-loss results for the two drugs come from separate trials and cannot be subtracted.","scope":{"population":"751 adults with obesity, without type 2 diabetes","design":"Randomized, open-label, phase 3b, 72 weeks, maximum tolerated doses","boundary":"This trial only. It says nothing about other doses, populations or outcomes."},"strongest":[{"label":"SURMOUNT-5, result surmount-5-weight-72w (Flagship Weight Management 1.3.0)","url":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=surmount-5-weight-72w","kind":"WPF record","population":"751 adults with obesity, without type 2 diabetes","design":"Randomized head-to-head, open-label","locator":"Point estimates: registry NCT05822830 results, primary outcome measure 1, posts -20.2 (tirzepatide) and -13.7 (semaglutide) as least-squares means, each with a standard error of 0.59, and a between-group least-squares mean difference of -6.5 (95% CI -8.1 to -4.9). The intervals -21.4 to -19.1 (tirzepatide's own mean) and -14.9 to -12.6 (semaglutide's own mean) and P<0.001 are from the NEJM abstract (PMID 40353578), not the registry; each belongs to one arm's mean, not to the difference between arms, and the abstract does not report the between-group difference."},{"label":"ClinicalTrials.gov NCT05822830","url":"https://clinicaltrials.gov/study/NCT05822830?tab=results","kind":"Registry record","population":"751 randomized (375 tirzepatide, 376 semaglutide)","design":"Registered phase 3b trial, results posted 2025-11-26","locator":"Results tab, participant flow: 319 of 375 and 319 of 376 completed the study."}],"uncertain":["The trial was open-label, so participants and investigators knew which drug they received.","The publication abstract does not name the estimand. WPF matched the displayed values to the analysis plan by method.","STEP 1 and SURMOUNT-1 are separate placebo-controlled trials; their percentages describe different populations and designs."],"wouldChange":["A second head-to-head trial with a different result, or a correction to the registry or publication."],"gaps":["The NEJM paper could not be opened by WPF's automated access (HTTP 403), so the table or figure that prints these numbers was not located."],"searchScope":null,"regulatory":null,"checkedOn":"2026-11-16","links":{"profiles":["/directory/tirzepatide","/directory/semaglutide"],"films":["/films/metabolic/06-semaglutide"],"flagship":["https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w"],"journeys":["/research/journey/semaglutide"],"teaching":["/research/teaching/weight-management-comparison"],"changes":[]},"extends1_0_0":true},"sha256":"f1cf06e3114e3786ae7b528224b2145dcad4800234936a529ae54e27ca2f0754"}